Ensuring continuity of care for patients living with Multiple Sclerosis (MS) during the COVID-19 pandemic is critical for providers and patients.
The impact of the pandemic on physical access to treatment and precautions that need to be taken by patient and provider are significant.
As stated by the National Multiple Sclerosis Society, “MS itself does not increase the risk of getting COVID-19, however, certain factors associated with your MS may increase your risk for complications:
moNATor® from Aegirbio measures the amount of Tysabri in an MS patient’s blood. This information may help optimize treatment intervals, reducing the risk of exposure to COVID-19 and also potentially reducing the risk of progressive multifocal leukoencephalopathy (PML).
If you’re impacted by multiple sclerosis (MS) you may know that using Tysabri (natalizumab), while clinically proven to be beneficial, comes with risks.
moNATor® from Aegirbio was designed to measure the amount of Tysabri in your blood. This information may help optimize your treatment intervals, potentially reducing PML risk.
A simple blood test (done right within your regular infusion routine) can provide data on which Tysabri (natalizumab) treatment interval may be appropriate for YOU.
The Magnia Point of Care / Point of Need table top reader uses magnetic technology to allow high sensitivity and accuracy quantitative readouts from disposable test strips.